These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 7549839)

  • 1. A randomized study of MOD versus VAD in the treatment of relapsed and resistant multiple myeloma.
    Phillips JK; Sherlaw-Johnson C; Pearce R; Davies JM; Reilly JT; Newland AC; Cawley JC
    Leuk Lymphoma; 1995 May; 17(5-6):465-72. PubMed ID: 7549839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].
    Luo SK; Li J; Hong WD; Zhao Y; Tong XZ
    Ai Zheng; 2005 Dec; 24(12):1518-21. PubMed ID: 16351805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
    Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
    Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.
    Cavo M; Benni M; Ronconi S; Fiacchini M; Gozzetti A; Zamagni E; Cellini C; Tosi P; Baccarani M; Tura S;
    Haematologica; 2002 Sep; 87(9):934-42. PubMed ID: 12217805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial.
    Rifkin RM; Gregory SA; Mohrbacher A; Hussein MA
    Cancer; 2006 Feb; 106(4):848-58. PubMed ID: 16404741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VAD regimen in the treatment of resistant multiple myeloma: slow or fast infusion?
    Koskela K; Pelliniemi TT; Remes K
    Leuk Lymphoma; 1993 Jul; 10(4-5):347-51. PubMed ID: 8220133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase III study comparing vincristine, doxorubicin (Adriamycin), and dexamethasone (VAD) chemotherapy with VAD plus recombinant interferon alfa-2 in refractory or relapsed multiple myeloma. An Eastern Cooperative Oncology Group study.
    Gertz MA; Kalish LA; Kyle RA; Hahn RG; Tormey DC; Oken MM
    Am J Clin Oncol; 1995 Dec; 18(6):475-80. PubMed ID: 8526187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group.
    Friedenberg WR; Rue M; Blood EA; Dalton WS; Shustik C; Larson RA; Sonneveld P; Greipp PR
    Cancer; 2006 Feb; 106(4):830-8. PubMed ID: 16419071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study.
    Dalton WS; Crowley JJ; Salmon SS; Grogan TM; Laufman LR; Weiss GR; Bonnet JD
    Cancer; 1995 Feb; 75(3):815-20. PubMed ID: 7828131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modified adriamycin-vincristine-dexamethasone (m-VAD) in primary refractory and relapsed plasma cell myeloma: an NCI (Canada) pilot study. The National Cancer Institute of Canada Clinical Trials Group.
    Browman GP; Belch A; Skillings J; Wilson K; Bergsagel D; Johnston D; Pater JL
    Br J Haematol; 1992 Nov; 82(3):555-9. PubMed ID: 1486035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914).
    Sonneveld P; Suciu S; Weijermans P; Beksac M; Neuwirtova R; Solbu G; Lokhorst H; van der Lelie J; Dohner H; Gerhartz H; Segeren CM; Willemze R; Lowenberg B; ; ;
    Br J Haematol; 2001 Dec; 115(4):895-902. PubMed ID: 11843823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HyperCVAD for VAD-resistant multiple myeloma.
    Dimopoulos MA; Weber D; Kantarjian H; Delasalle KB; Alexanian R
    Am J Hematol; 1996 Jun; 52(2):77-81. PubMed ID: 8638645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etoposide, dexamethasone, cytarabine, and cisplatin in vincristine, doxorubicin, and dexamethasone-refractory myeloma.
    Barlogie B; Velasquez WS; Alexanian R; Cabanillas F
    J Clin Oncol; 1989 Oct; 7(10):1514-7. PubMed ID: 2778481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma.
    Dimopoulos MA; Pouli A; Zervas K; Grigoraki V; Symeonidis A; Repoussis P; Mitsouli C; Papanastasiou C; Margaritis D; Tokmaktsis A; Katodritou I; Kokkini G; Terpos E; Vyniou N; Tzilianos M; Chatzivassili A; Kyrtsonis MC; Panayiotidis P; Maniatis A;
    Ann Oncol; 2003 Jul; 14(7):1039-44. PubMed ID: 12853344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized study (WOS MM1) comparing the oral regime Z-Dex (idarubicin and dexamethasone) with vincristine, adriamycin and dexamethasone as induction therapy for newly diagnosed patients with multiple myeloma.
    Cook G; Clark RE; Morris TC; Robertson M; Lucie NP; Anderson S; Paul J; Franklin IM
    Br J Haematol; 2004 Sep; 126(6):792-8. PubMed ID: 15352982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistant multiple myeloma treated with mitozantrone in combination with vincristine and dexamethasone (MOD).
    Phillips JK
    Eur J Haematol; 1989 Jan; 42(1):109-10. PubMed ID: 2914592
    [No Abstract]   [Full Text] [Related]  

  • 17. Therapy of primary resistant and relapsed multiple myeloma.
    Barlogie B; Alexanian R
    Onkologie; 1986 Aug; 9(4):210-4. PubMed ID: 3531948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of rhIL-6 (interleukin-6) prior to and concurrently with VAD (vincristine, doxorubicin and dexamethasone) chemotherapy for patients with multiple myeloma.
    Young RI; Ranson M; Chang J; Lord B; Testa N; Scarffe JH
    Eur J Cancer; 1997 Feb; 33(2):307-11. PubMed ID: 9135507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON.
    Sonneveld P; Durie BG; Lokhorst HM; Marie JP; Solbu G; Suciu S; Zittoun R; Löwenberg B; Nooter K
    Lancet; 1992 Aug; 340(8814):255-9. PubMed ID: 1353189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VAD-based regimens as primary treatment for multiple myeloma.
    Alexanian R; Barlogie B; Tucker S
    Am J Hematol; 1990 Feb; 33(2):86-9. PubMed ID: 2301376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.